2021
Adjunct Fenofibrate Up‐regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis
Gallucci GM, Trottier J, Hemme C, Assis DN, Boyer JL, Barbier O, Ghonem NS. Adjunct Fenofibrate Up‐regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis. Hepatology Communications 2021, 5: 2035-2051. PMID: 34558841, PMCID: PMC8631103, DOI: 10.1002/hep4.1787.Peer-Reviewed Original ResearchConceptsSerum bile acidsSerum alkaline phosphataseBile acidsTreatment responseIncomplete responseTotal serum bile acidsElevated serum alkaline phosphatasePeroxisome proliferator-activated receptor alphaProliferator-activated receptor alphaAlkaline phosphatasePrimary sclerosing cholangitisPrimary biliary cholangitisStandard of careSerum ALP levelsBile acid glucuronidationCytotoxic bile acidsPrimary human hepatocytesBA detoxificationFenofibrate therapySclerosing cholangitisAdult patientsBiliary cholangitisLiver failureCombination therapyImproved outcomes
2020
Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol
Ghonem NS, Auclair AM, Hemme CL, Gallucci GM, de la Rosa Rodriguez R, Boyer JL, Assis DN. Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol. Clinical Pharmacology & Therapeutics 2020, 108: 1213-1223. PMID: 32480421, PMCID: PMC7886378, DOI: 10.1002/cpt.1930.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBile Acids and SaltsBiomarkersCholangitis, SclerosingCytokinesDrug Therapy, CombinationFemaleFenofibrateHumansInflammation MediatorsLiverLiver Cirrhosis, BiliaryLiver Function TestsMaleMiddle AgedPPAR alphaPrincipal Component AnalysisRetrospective StudiesTreatment OutcomeUrsodeoxycholic AcidYoung AdultConceptsPrimary sclerosing cholangitisPrimary biliary cholangitisBile acid metabolismSclerosing cholangitisBiliary cholangitisBile acidsAcid metabolismPeroxisome proliferator-activated receptor alphaProliferator-activated receptor alphaRetrospective observational studyBeneficial clinical effectsCholestatic liver diseasePro-inflammatory cytokinesBile acid metabolitesHealthy control subjectsBile acid poolSerum alkaline phosphataseAminotransferase abnormalitiesUrsodiol therapyFenofibrate therapyPartial respondersBile acid precursorsClinical effectsFenofibrate treatmentLiver disease
2017
Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis
Assis DN, Abdelghany O, Cai SY, Gossard AA, Eaton JE, Keach JC, Deng Y, Setchell KD, Ciarleglio M, Lindor KD, Boyer JL. Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis. Journal Of Clinical Gastroenterology 2017, 51: e11-e16. PMID: 27428727, PMCID: PMC5218875, DOI: 10.1097/mcg.0000000000000591.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAlanine TransaminaseAlkaline PhosphataseBile Acids and SaltsCholagogues and CholereticsCholangitis, SclerosingCholestenonesDrug Therapy, CombinationFemaleHumansLiverLiver Function TestsMaleMiddle AgedPilot ProjectsTreatment OutcomeTretinoinUrsodeoxycholic AcidYoung AdultConceptsPrimary sclerosing cholangitisUrsodeoxycholic acidAlanine aminotransferaseUDCA monotherapyPrimary endpointSclerosing cholangitisMedian serum alanine aminotransferasePilot studyWeeks of therapyMarkers of inflammationSerum alanine aminotransferaseRetinoic acidAlkaline phosphataseAll-Trans Retinoic AcidSerum ALP levelsHuman pilot studyCombination of ATRAAddition of ATRABile acid synthesisTrans retinoic acidExploratory pilot studyALT levelsAccepted therapyWeek 12C4 levels
1980
Aminopyrine n-Demethylation: A Prognostic test of liver function in patients with alcoholic liver disease
Schneider J, Baker A, Haines N, Hatfield G, Boyer J. Aminopyrine n-Demethylation: A Prognostic test of liver function in patients with alcoholic liver disease. Gastroenterology 1980, 79: 1145-1150. PMID: 6777231, DOI: 10.1016/0016-5085(80)90906-3.Peer-Reviewed Original ResearchConceptsAminopyrine breath testAlcoholic liver diseaseBreath testLiver diseaseAlcoholic hepatitisClinical improvementHistologic severityLiver functionConventional liver function testsLiver function testsGroup of patientsShort-term survivalClinical featuresFunction testsHistologic confirmationClinical statusProthrombin timePatientsPrognostic testDiseaseHepatitisSeveritySurvivalSGPTSGOT
1977
Taurolithocholate-Induced Cholestasis: Taurocholate, but not Dehydrocholate, Reverses Cholestasis and Bile Canalicular Membrane Injury
Layden T, Boyer J. Taurolithocholate-Induced Cholestasis: Taurocholate, but not Dehydrocholate, Reverses Cholestasis and Bile Canalicular Membrane Injury. Gastroenterology 1977, 73: 120-128. PMID: 863183, DOI: 10.1016/s0016-5085(19)32283-8.Peer-Reviewed Original ResearchEvaluation of a New Monkey Model for the Repeated Study of Bile Secretory Physiology
WOOD R, BAKER A, HALL A, BOYER J, MOOSSA A. Evaluation of a New Monkey Model for the Repeated Study of Bile Secretory Physiology. Annals Of Surgery 1977, 185: 349-355. PMID: 402891, PMCID: PMC1396621, DOI: 10.1097/00000658-197703000-00017.Peer-Reviewed Original ResearchConceptsBile flowSecretory physiologyMonkey modelBile salt secretion rateFinal infusion rateBile salt excretionBile salt outputHigher bile flowNew monkey modelSalt secretion rateBicarbonate outputPostoperative managementInfusion rateTaurocholate infusionSalt outputSalt excretionSecretion rateLong-term studiesRandom orderPeriod of monthsSecretinClearance